Antinociceptive mechanisms of orally administered decursinol in the mouse.
Antinociceptive profiles of decursinol were examined in ICR mice. Decursinol administered orally (from 5 to 200 mg/kg) showed an antinociceptive effect in a dose-dependent manner as measured by the tail-flick and hot-plate tests. In addition, decursinol attenuated dose-dependently the writhing numbers in the acetic acid-induced writhing test. Moreover, the cumulative response time of nociceptive behaviors induced by an intraplantar formalin injection was reduced by decursinol treatment during the both 1st and 2nd phases in a dose-dependent manner. Furthermore, the cumulative nociceptive response time for intrathecal (i.t.) injection of TNF-alpha (100 pg), IL-1 beta (100 pg), IFN-gamma (100 pg), substance P (0.7 microg) or glutamate (20 microg) was dose-dependently diminished by decursinol. Intraperitoneal (i.p.) pretreatment with yohimbine, methysergide, cyproheptadine, ranitidine, or 3,7-dimethyl-1-propargylxanthine (DMPX) attenuated inhibition of the tail-flick response induced by decursinol. However, naloxone, thioperamide, or 1,3-dipropyl-8-(2-amino-4-chloro-phenyl)-xanthine (PACPX) did not affect inhibition of the tail-flick response induced by decursinol. Our results suggests that decursinol shows an antinociceptive property in various pain models. Furthermore, antinociception of decursinol may be mediated by noradrenergic, serotonergic, adenosine A(2), histamine H(1) and H(2) receptors.
Choi
Seong-Soo
SS
Department of Pharmacology, College of Medicine, and Institute of Natural Medicine, Hallym University, 1 Okchun-dong, Chunchon, Kangwon Do, 200-702, South Korea.
Han
Ki-Jung
KJ
Lee
Jin-Koo
JK
Lee
Han-Kyu
HK
Han
Eun-Jung
EJ
Kim
Do-Hoon
DH
Suh
Hong-Won
HW
D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D001578:Benzopyrans / Q000008:administration & dosage* / Q000494:pharmacology*; D002087:Butyrates / Q000008:administration & dosage* / Q000494:pharmacology*; D003533:Cyproheptadine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018698:Glutamic Acid / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D008297:Male; D008784:Methysergide / Q000494:pharmacology; D051379:Mice; D008813:Mice, Inbred ICR; D008956:Models, Chemical; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010146:Pain / Q000188:drug therapy*; D010880:Piperidines / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D011899:Ranitidine / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000378:metabolism; D011968:Receptors, Histamine / Q000378:metabolism; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology; D013805:Theobromine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000700:Analgesics; D001578:Benzopyrans; D002087:Butyrates; D006635:Histamine H2 Antagonists; D007375:Interleukin-1; D009292:Narcotic Antagonists; D010880:Piperidines; D011941:Receptors, Adrenergic; D011968:Receptors, Histamine; D018047:Receptors, Purinergic P1; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D014409:Tumor Necrosis Factor-alpha; D014970:Xanthines; D015016:Yohimbine; D003533:Cyproheptadine; D013373:Substance P; D009270:Naloxone; D018698:Glutamic Acid; C057837:3,7-dimethyl-1-propargylxanthine; D007371:Interferon-gamma; D011899:Ranitidine; C101278:decursin; D011493:Protein Kinase C; C046379:1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine; C052075:thioperamide; D013805:Theobromine; D008784:Methysergide